3,0
21. Juni 2016
Mitarbeiter (anonym)
Aktueller Mitarbeiter, mehr als 3 Jahre
Singapur
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
They have smart, helpful folks working in global roles in the functional areas. Company pipeline is promising, especially in the area of oncology.
Kontras
Regional and local leaders are lacking in strategy and direction, making frequent changes reflects poorly on them to customers. Still very much a primary care company in the throes of pain transiting to a specialty care one.